Testing requirements, drug interactions hamper use of Pfizer COVID-19 antiviral pill
Worldwide demand for Pfizer Inc's PFE.N oral COVID-19 antiviral treatment Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions, a Reuters review of data and interviews with experts has found.